Objective-Small GTPase Ras-related protein 1 (Rap1b) controls several basic cellular phenomena, and its deletion in mice leads to several cardiovascular defects, including impaired adhesion of blood cells and defective angiogenesis. We found that Rap1b −/− mice develop cardiac hypertrophy and hypertension. Therefore, we examined the function of Rap1b in regulation of blood pressure. Approach and Results-Rap1b −/− mice developed cardiac hypertrophy and elevated blood pressure, but maintained a normal heart rate. Correcting elevated blood pressure with losartan, an angiotensin II type 1 receptor antagonist, alleviated cardiac hypertrophy in Rap1b −/− mice, suggesting a possibility that cardiac hypertrophy develops secondary to hypertension. The indices of renal function and plasma renin activity were normal in Rap1b −/− mice. Ex vivo, we examined whether the effect of Rap1b deletion on smooth muscle-mediated vessel contraction and endothelium-dependent vessel dilation, 2 major mechanisms controlling basal vascular tone, was the basis for the hypertension. We found increased contractility on stimulation with a thromboxane analog or angiotensin II or phenylephrine along with increased inhibitory phosphorylation of myosin phosphatase under basal conditions consistent with elevated basal tone and the observed hypertension. Cyclic adenosine monophosphate-dependent relaxation in response to Rap1 activator, Epac, was decreased in vessels from Rap1b −/− mice. Defective endothelial release of dilatory nitric oxide in response to elevated blood flow leads to hypertension. We found that nitric oxide-dependent vasodilation was significantly inhibited in Rap1b-deficient vessels. Conclusions-This is the first report to indicate that Rap1b in both smooth muscle and endothelium plays a key role in maintaining blood pressure by controlling normal vascular tone. (Arterioscler Thromb Vasc The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
A rterial hypertension, a persistent elevation in blood pressure, is a major health problem and a risk factor for several cardiovascular diseases. 1 The common observation in hypertension is elevated arteriolar resistance because of increased vascular tone. Vascular smooth muscle (SM)-mediated vessel contraction and endothelium-dependent vessel vasodilation are 2 of the major mechanisms controlling basal vascular tone. SM tone is regulated by neural, humoral, and rheological stimuli that converge on myosin regulatory light chain (RLC 20 ) phosphorylation, which promotes actomyosin contractility. Agonistinduced activation of small GTPase RhoA and its target Rho kinase leads to increased inhibitory phosphorylation of myosin light chain phosphatase and increasing RLC 20 phosphorylation (Ca 2+ sensitization). [2] [3] [4] In contrast, elevation of intracellular second messengers, cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate, reduces Ca 2+ sensitivity and induces SM relaxation (Ca 2+ desensitization). 5, 6 Increased SM contractility is counterbalanced by relaxing factors such as prostacyclin, endothelium-derived hyperpolarizing factor, and nitric oxide (NO), that are released from endothelium on increased flow shear stress. 7 Decreased NO production, a hallmark of endothelial dysfunction, leads to hypertension. 8, 9 Ras-related protein 1 (Rap1) is a ubiquitously expressed small GTPase that integrates signals from multiple receptors to control several basic cellular phenomena including adhesion, polarity, and migration. 10 Two Rap1 isoforms exist, Rap1a and Rap1b; deletion of both isoforms leads to embryonic lethality, 11 and deletion of either gene leads to several cardiovascular defects, including impaired vascular adhesion of various blood cell populations [12] [13] [14] and altered angiogenesis. [15] [16] [17] In addition to described defects, our observation of frequent increased neonatal lethality and sudden death in male Rap1b −/− mice suggested severe underlying defects in cardiovascular function. In this article, we report that Rap1b −/− mice are hypertensive and develop cardiac hypertrophy. We hypothesize that vascular Rap1 deficiency in blood vessels increases vascular tone, resulting in hypertension. We show that Rap1b in SM and endothelium contributes to elevated vascular tone. Mechanistically, in SM, Rap1b counteracted RhoA-dependent Ca 2+ sensitization.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Global Rap1b Deficiency Leads to Hypertension and Cardiac Hypertrophy
We observed that, in addition to previously described phenotypes, 12, 15, 17 Rap1b −/− mice have an increased heart-tobody weight ratio because of grossly enlarged heart weight ( Figure 1A and 1B; Figure IA in the online-only Data Supplement) and increased dimensions ( Figure 1C ; Table) , resulting partly from enlarged cardiomyocytes ( Figure 1D ). This remodeling response was accompanied by increased cardiac fibrosis ( Figure 1E ) with evidence of emerging diastolic dysfunction (increased mitral E-wave deceleration times; Table) and macrophage infiltration ( Figure 1F ), all consistent with pathological hypertrophy. Because such changes often are maladaptive and secondary to hypertension, 1 we performed telemetric blood pressure measurements. We found that Rap1b −/− mice had significantly elevated blood pressure (135±6 versus 108±1 mm Hg; wild type [WT]; n≥4; Figure 2A -2C), but normal heart rate (514±15 versus 511±9 beats per minute; WT; n=4; Table) . To test whether cardiac hypertrophy is secondary to elevated blood pressure in Rap1b −/− mice, we examined the effect of blood pressure-controlling medication on the development of cardiac hypertrophy in Rap1b −/− mice. To control hypertension, Rap1b −/− mice were chronically treated with losartan, 18 a competitive inhibitor of angiotensin II type 1 receptor (AT 1 R). AT 1 R inhibitors have been demonstrated to prevent pressure overload-induced left ventricular hypertrophy in mouse models. 19 After 8 to 12 weeks of treatment, blood pressure, heart, and body weights of treated animals were measured and compared with untreated controls. Systolic blood pressure in 8-to 12-weekold Rap1b −/− untreated mice ( Figure 2D ) was elevated compared with untreated WT mice, but lower than that in 6-to 10-month-old Rap1b −/− mice (Figure 2A ). Importantly, correcting elevated blood pressure with losartan treatment ( Figure 2D ) led to decreased heart-to-body weight ratio and alleviated cardiac hypertrophy in Rap1b −/− mice ( Figure 2E ), suggesting that cardiac hypertrophy may be secondary to hypertension in Rap1b −/− mice. However, AT 1 R antagonist may have a direct effect on cardiomyocytes. 20 We, therefore, attempted to correct elevated blood pressure with an antihypertensive drug hydralazine 21 and examined the effect of this treatment on cardiac hypertrophy. We found that hydralazine treatment corrected elevated blood pressure in Rap1b −/− mice Nonstandard Abbreviations and Acronyms AT ( Figure 2F ), but also led to increased heart-to-body weight ratio in WT, but not in Rap1b −/− mice ( Figure 2G ). Although the difference in heart-to-body weight ratios between these groups tended to be smaller, in particular in older animals (data not shown), cardiac hypertrophy was not corrected in Rap1b −/− mice ( Figure 2G ). A similar lack of effect on cardiac hypertrophy was obtained when hydralazine was used to lower blood pressure in human hypertensive subjects and animal hypertensive models. [22] [23] [24] Therefore, it is possible that Rap1 deficiency in cardiomyocytes directly contributes to cardiac hypertrophy.
Increased Basal and Agonist-Induced Contraction and Suppressed Relaxation in Rap1b −/− SM
Indices of renal function and activation of the renin-angiotensin-aldosterone system were assessed to determine the contribution of these systems to the observed phenotype. We observed that plasma renin activity, plasma creatinine concentration, and urine albumin/creatinine excretion ratio ( Figure 3 ) were within the normal range of values reported for mice, 25, 26 and renal histology, as evaluated by Masson trichrome and H&E staining ( Figure 4 ), was not different between WT and Rap1b −/− mice. Therefore, we concluded that defects in renal function or in the activation of the circulating renin-angiotensin system are not causes of elevated blood pressure in Rap1b −/− mice and placed our efforts into the elucidation of altered vascular contractility responses.
To determine whether Rap1 deletion leads to increased vascular tone, we measured contraction of endothelium-denuded aortic segments isolated from Rap1b −/− and control mice. Although aorta has limited contribution to the overall blood pressure level, ex vivo analysis of aortic SM contractility is an accepted model to study underlying mechanisms of SM contraction and was used by Furchgott 27 in the landmark discovery of endothelium-derived relaxing factor. SM contractility is regulated by a Ca 2+ -dependent component and a Ca 2+ -independent component, the latter modulated by small GTPase RhoA. For various agonists, the amount of force to calcium signal differs, and one agonist that promotes contractility via the RhoA component is prostanoid thromboxane A2, a potent vasoconstrictor implicated in hypertension and acting via thromboxane prostanoid receptor. 28 Thromboxane-induced activation of RhoA and its target Rho kinase leads to increased inhibitory phosphorylation of myosin light chain phosphatase, increasing RLC 20 phosphorylation (Ca 2+ sensitization). [2] [3] [4] Because our previous work suggested that Rap1 may regulate contractility by regulating RhoA, 29 we examined SM contractility in response to thromboxane analog, 9,11-dideoxy-9a,11a-methanoepoxy prostaglandin F2α (U46619), which activates Rap1. 29 We found a significant increase in contractile force in Rap1b −/− segments ( Figure 5A and 5B; Table I in the online-only Data Supplement).
To examine the underlying mechanism of increased contraction in Rap1b −/− denuded aortic segments, we examined the effect of Rap1 deficiency on expression and activity of the contractile apparatus components. Because hypertension is known to cause vascular remodeling, we investigated aortic morphology to determine whether an increased thickness in the medium layer may contribute to the enhanced contractile responses. We found no gross differences in diameter and wall thickness between WT and Rap1b −/− vessels when examined under a dissecting microscope. We also found no changes in the expression of actin or myosin ( Figure 6A ) in aortic strips of the same length and width from these mice. Lastly, we measured maximum force induced by high K + depolarization in strips that were cut at identical widths, and therefore force is only a function of the cross-sectional area of the strip. We found no difference in the maximum high K + -induced force in WT and Rap1b −/− aortae ( Figure 5C ), consistent with identical cross-sectional areas. Therefore, we conclude that these vessels contain the same amount of SM, and there is no hypertrophy in the vessel wall.
Importantly, however, the average basal level of phosphorylation of MYPT1/Thr853 (Rho kinase site) was significantly elevated by 2-fold ( Figure 6B ), which, with unchanged K +induced maximum contraction ( Figure 5C ), suggested selectivity of the effect of Rap1b deletion on RhoA/Rho kinase signaling, and not changes in calcium homeostasis. Stimulation with the thromboxane analog, U46619, led to increased phosphorylation of RLC 20 and MYPT1 at Thr853 during 5 minutes of treatment in WT aortae and a significantly higher increase in Rap1b −/− aortae, indicative of increased RhoA activity ( Figure 6C ). Note that the U46619-induced increases in RLC 20 and MYPT1/Thr853 phosphorylation are each normalized to a paired nonstimulated muscle for comparison of the magnitudes of U46619-induced changes and thus do not reflect the increased basal phosphorylation shown in Figure 6B .
To examine whether SM contractility is altered in response to other agonists associated with hypertension, we examined contractile responses to angiogensin II. Angiogensin II is known to activate Rap1, 20, 30 and in SM it also activates the RhoA-mediated component. 31, 32 We found that the contractile responses were significantly elevated in Rap1b −/− aortae in response to angiotensin II ( Figure 5D ), whereas the expression of AT 1 R was unchanged ( Figure 5E ). Furthermore, because sympathetic system plays a critical role in maintaining basal blood pressure, we examined the contractile response to phenylephrine, an adrenergic receptor agonist, and found that it was also increased in Rap1b −/− aortae ( Figure 5F ). We, therefore, conclude that Rap1b modulation of agonist-induced SM contraction is not selective to U46619. These data show that Rap1b suppresses agonist-induced force and suggest that Rap1b is required to suppress RhoA activity, and that elevation of RhoA activity leading to inhibitory phosphorylation of myosin light chain phosphatase and increased RLC 20 phosphorylation may contribute to increased basal tone and hypertension in Rap1b −/− mice.
SM tone is modulated under physiological conditions by cAMP 5, 33 and perturbed in disease states, such as obstructive pulmonary diseases and asthma. 34 We have recently demonstrated that elevation of cAMP with 8-pCPT-2′-O-Me-cAMP (007), a cAMP analog that selectively activates Epac, a Rap1 GTP exchange factor, induces SM relaxation by downregulation of RhoA activity. 29 To directly test whether Rap1 is involved in this mechanism of cAMP-dependent Ca 2+ desensitization and SM relaxation, we measured in WT and Rap1b −/− aortae the U46619 dose-force relationship in the presence and absence of 007. Although 007 significantly increased U46619 EC 50 values ( Table I in the online-only Data Supplement) and suppressed force curves in both WT ( Figure 5A , open versus filled squares) and Rap1b −/− aortae ( Figure 5A , open versus filled circles), it was unable to reduce the force in Rap1b −/− segments to the level of WT controls ( Figure 5A , open circles are upward shifted compared with open squares; the effect of 007 on contraction is blunted), consistent with a role for Epac in the Rap1b-mediated suppression of RhoA-mediated force ( Figure 6A ; Table I in the online-only Data Supplement).
Endothelial Dysfunction and Decreased Endothelial NO Synthase Activity in Rap1b −/− Mice
In response to turbulent or laminar blood flow, humoral factors, and increased SM contraction, endothelial cells (ECs) secrete vasodilator substances that relax SM to maintain normal blood pressure. Of these, NO is particularly important for relaxation of large vessels, including the aorta. Because Rap1b −/− mice showed increased vasoconstriction ( Figure 5 ) and developed hypertension (Figure 2) , we examined the effect of Rap1b deficiency on vessel dilation, a defect in NO-dependent vasodilation would likely lead to increased vascular tone and hypertension. 8, 9 Acetylcholine is a potent vasodilator acting via G-protein-coupled muscarinic receptors, and Rap1 has been previously implicated in signaling pathways downstream from M(1) subtype of muscarinic acetylcholine receptor. 35 Acetylcholine-induced, NO-dependent dilation was significantly reduced in Rap1b −/− aortic segments preconstricted with U46619 ( Figure 7A ; black line, Rap1b −/− ; grey line, WT; Table  II in the online-only Data Supplement) or with methoxamine (data not shown). To distinguish whether Rap1 regulates NO release from ECs or NO sensitivity of SM, we blocked NO release with l-NG-nitro arginine methyl ester and measured vasodilation in the presence of sodium nitroprusside. We did not observe a significant difference in the extent of vasodilation between WT and Rap1b −/− aortic segments ( Figure 7B ), which suggests that Rap1 is required for optimal NO release by endothelium and not for regulation of NO sensitivity.
To further examine the defect in NO-dependent dilation, we generated EC-restricted Rap1b-knockout mice (Tie2-Cre +/0 Rap1b f/f ; Rap1b-ECKO) and measured NO-mediated relaxation in vessels from these mice. We found that NO-dependent, acetylcholine-induced vasodilation was decreased ( Figure 7A , dashed line; Table II in the online-only Data Supplement), whereas SM sensitivity was unchanged ( Figure 7B , dashed line) in Rap1b-ECKO aortae, similar to what we found in Rap1b −/− aortae ( Figure 7A and 7B, black lines). These results suggest that a defect in EC is responsible for decreased NO bioavailability. In blood vessels, NO is produced by endothelial NO synthase (eNOS), the activity of which is regulated by Ca 2+ /calmodulin, binding of regulatory cofactors, and post-translational modifications including phosphorylation of Ser1177, which sensitizes eNOS to Ca 2 , stimulating NO production. [36] [37] [38] To determine whether decreased eNOS activity is responsible for decreased NO production in Rap1b-deficient ECs, we examined agonist-induced phosphorylation of eNOS at Ser1177. 39 Treatment of WT ECs with VEGF led to a significant induction of eNOS/Ser1177 phosphorylation, an effect that was significantly decreased in Rap1b-deficient ECs, indicating decreased eNOS activity in these cells ( Figure 7C ).
Together, these findings underscore the importance of Rap1 in both cellular compartments, EC and SM, in vascular tone control.
Discussion
The major finding of this study is that Rap1b plays a critical role in the regulation of vascular tone and blood pressure by controlling responses of endothelium and SM, 2 interdependent cell types coordinating the relaxation-contraction mechanism in blood vessels. In SM, denuded of endothelium, we show that Rap1b regulates basal tone and mediates cAMP-induced desensitization of contraction. Rap1b suppresses RhoA-mediated RLC 20 phosphorylation, Ca +2 sensitization, and relaxation, signaling that is further enhanced on cAMP-dependent activation of Rap1 by Epac ( Figure 6D ). Ex vivo, we show that Rap1b is essential for regulation of vasodilation in EC-autonomous manner, because Rap1b deficiency leads to a significant decrease in NO-dependent vasodilation, a novel and physiologically important function of Rap1b. In vitro, we show that underlying the defect in NO-dependent vasodilation is decreased eNOS activation in Rap1b-deficient ECs. Together, Rap1b function in both cell types is important for regulation of vascular tone. The significance and novelty of our findings is underscored by the phenotype of Rap1b-deficient mice, which includes endothelial dysfunction and hypertension.
Regulation of vascular tone and blood pressure by Rap1b may be one of its physiologically most critical functions in the cardiovascular system in adult mice, compared with relatively mild defects reported so far in other systems. [12] [13] [14] [15] 40, 41 Furthermore, it may help explain the lethality during embryonic development that we had previously described, 12 which includes hemorrhage on the side of the head after embryonic day E12.5. Although no specific primary vascular defects have been observed in Rap1b −/− embryos, abnormal vascular tone may constitute a hemodynamic or physiological abnormality underlying the observed embryo lethality. 11 Although our study points to key functions of Rap1b in SM and endothelium in control of blood pressure, blood pressure is regulated by several mechanisms. 42 Here we show that Rap1b in kidney does not have a major function in that process, because we have observed normal gross kidney histology and no major changes in indices of renal function or plasma renin activity in Rap1b −/− mice. However, several additional studies would need to be performed to fully understand the role of Rap1b in kidney function 43 and in regulation of tissue renin-angiotensin system, which also contributes to blood pressure regulation. Likewise, it is conceivable that Rap1b in the sympathetic nervous system contributes to the regulation of blood pressure. Although future studies should explore the contribution of Rap1b in the sympathetic nervous system to the regulation of blood pressure, our current findings demonstrate that Rap1b functions in vessels are critical for vascular tone.
The phenotype of Rap1b-deficient mice is consistent with Rap1's role in hypertension and cardiac disease. We have not found any reports of changes in Rap1 expression in hypertension; interestingly, though, a genome-wide expression profiling study reported upregulated expression of a negative regulator of Rap1 activity, Rap1GAP, in lungs of patients with idiopathic pulmonary hypertension, 44 a change that would be expected to lead to decreased Rap1 activity and increased airway resistance. Our findings implicating Rap1b in regulation of vascular tone provide justification for additional examination of Rap1b activity in samples from hypertensive patients. Additonal studies are also needed to fully elucidate molecular mechanisms of Rap1b-mediated downregulation of RhoA activity in SM. In other cell types, 2 different RhoGAPs have been implicated in playing this role: ARAP3, which is involved in regulation of neurite outgrowth, 45, 46 male germ cell development, 47 and monocyte migration 48 ; and ArhGAP29, 49 which promotes EC spreading and barrier function. 50 Identification of the molecular connection between Rap1 and RhoA in SM is our future area of investigation.
Several studies have linked increased Epac activity with cardiac hypertrophy 51 ; Epac expression correlates with pathological cardiac hypertrophy, 52 and, conversely, silencing Epac expression blocks the hypertrophic response. 53 However, prohypertrophic Epac signaling is not mediated by Rap1, but rather by Epac's other effectors, Rac1 and H-Ras. 54 In this study, we report that correction of elevated blood pressure with AT 1 R antagonist, losartan, ameliorates cardiac hypertrophy phenotype in Rap1b −/− mice. Although this novel finding is consistent with hypertrophy being secondary to elevated vascular tone and blood pressure, both AT 1 R and Rap1 are expressed in cardiomyocytes, and the effect of losartan could be cardiomyocyte-autonomous. 20 Nonetheless, Rap1 may be involved in other functions in cardiomyocytes; for example, Rap1 signaling has been implicated in cardioprotection from myocyte death induced by chronic adrenergic stimulation during congestive heart failure. 55 Therefore, Rap1 function in the heart deserves a separate investigation.
In conclusion, through distinct signaling mechanisms, the role of Rap1 in the endothelium and in SM is mutually reinforcing, having key mechanoeffector functions required for maintenance of normal vascular tone.
Increased vascular tone is a common observation in arterial hypertension, a major health problem and a risk factor for several cardiovascular diseases. Two of the major mechanisms controlling basal vascular tone are vascular smooth muscle-mediated vessel contraction and endothelium-dependent vessel vasodilation mediated by relaxing substances released in response to elevated shear flow of blood. Here, we demonstrate that a small GTPase Ras-related protein 1 (Rap1b) critically regulates both of these processes. Using Rap1b-deficient mice, we show that Rap1b regulates basal smooth muscle tone and mediates cyclic adenosine monophosphate-induced relaxation. In endothelium, Rap1b is essential for regulation of vasodilation, because Rap1b deficiency leads to a significant decrease in nitric oxide-dependent vasodilation. The significance of our findings is underscored by the phenotype of Rap1b-knockout mice, which includes hypertension and endothelial dysfunction. This report reveals a novel, physiologically important function of Rap1b and contributes to our understanding of the mechanisms of blood pressure regulation.
Significance
